我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
未知生产厂商
NT219 is a novel small molecule that acts as a dual inhibitor, simultaneously targeting IRS1/2 and STAT3.
NT219 is in a Phase 2 study for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.